Mulay James 4

What Happened

• James Mulay, a director of CG Oncology, was granted a derivative award (an option) covering 9,354 shares on 2026-06-04. The reported transaction shows $0.00 paid at grant (no cash outlay recorded in the filing). This is a grant/award (transaction code A), not a purchase or sale.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-05 (appears to be filed promptly).
• Reported amount: 9,354 shares granted as a derivative award; grant recorded at $0.00 (no cash paid).
• Vesting: 1/12th of the total option vests monthly following June 4, 2026; if the next annual meeting occurs before the first anniversary, any remaining unvested portion vests at that meeting, subject to continuous service (per footnote).
• Shares owned after the transaction: not specified in the provided excerpt of the filing.
• Transaction type: Award/Grant of an option (derivative). No exercise or sale occurred.

Context

• This is a grant of an equity award (option) to an insider, common as part of compensation or retention; it does not represent a market buy or sell. The filing shows no immediate exercise or cashless sale — future value depends on vesting and any exercise terms not shown in the excerpt.